Worth Venture Partners’s GSK GSK Stock Holding History

Worth Venture Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-39,900	Closed	-$18K	–	184
2022 Q3	$18K	Buy	+39,900	New	+$1.51M	0.01%	157

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Worth Venture Partners's GSK Position: Q4 2023 in Review

Worth Venture Partners sold out of GSK (GSK) in Q4 2023, closing a stake of 14,900 shares — an estimated $540K sold.

Worth Venture Partners first reported a position in GSK in Q4 2022 and held it in 4 quarters. The position peaked at $1.36M in Q1 2023. 895 funds tracked by Wall St. Rank hold GSK as of Q4 2023.

Worth Venture Partners reported no remaining GSK position as of Q4 2023 after selling out during the quarter.
Worth Venture Partners sold 14,900 GSK shares in Q4 2023, an estimated $540K.
Worth Venture Partners first reported a position in GSK in Q4 2022 and held it in 4 quarters.
Worth Venture Partners's GSK position peaked at $1.36M in Q1 2023.
895 funds tracked by Wall St. Rank held GSK as of Q4 2023.

Based on Worth Venture Partners's 13F filing for Q4 2023, filed 9 Feb 2024.